

Index

A

- Abnormal uterine bleeding (AUB), 95
- Acute coronary syndromes (ACS), 2
 - age and gender, 55–57
 - bleeding risk
 - after coronary interventions, 60
 - vaginal, with antiplatelet therapy, 60–61
 - management, 59–60
 - pathophysiology, 57–58
 - in pregnancy, 68
- SCAD
 - fibromuscular dysplasia, 63–65
 - involved coronary artery in, 62
 - prevalence, 61
 - symptom, 58–59
 - takotsubo cardiomyopathy, 65–67
- Anger, 204
- Angina pectoris, 47
- Angiotensin-1 receptor blockers (ARB), 129
- Anthracyclines, 121, 122
- Anxiety
 - chest pain, 211–212
 - ischemic heart disease, 204
- Aortic stenosis (AS)
 - diagnosis, 142–144
 - epidemiology, 142
 - treatment, 144
- Arrhythmias, 129
- Arterial stiffness, 91
- Atrial fibrillation (AF)
 - electrocardiography, 157–158
 - stroke, 187–188
- Atrioventricular nodal re-entrant tachycardias (AVNRT), 155–157
- Autonomic dysfunction, 208

B

- Beta-blockers, 129, 225
- Blood pressure, 93–95, 122
- BRCA mutation carriers, 120
- BRCA1/2 mutation carriers, 90
- Breast cancer (BC)
 - chemotherapy, 121
 - CVD
 - baseline risk factors, 120
 - BRCA mutation carriers, 120
 - death, 118
 - multiple-hit hypothesis, 118
 - optimal cardiac surveillance and treatment, 122–124
 - patient surveillance, 119
 - with anti-angiogenic and endocrine therapy, 122
 - immuno-and targeted therapy, 121–122
 - radiation therapy, 121
 - survival rates, 117
- Breast tissue, 154
- Bromocriptine, 128
- Brugada syndrome, 158

C

- Cardiac rehabilitation (CR)
 - barriers, 177–178
 - clinical cases, 169–174
 - lifestyle changes, 167
 - participation, 168
 - secondary prevention goals, 167–169
 - treatment
 - diet, 176
 - physical activity, 174–175

Cardiac rehabilitation (CR) (*cont.*)
 psychosocial stress, 176–177
 weight loss, 175–176

Cardiac resynchronization therapy (CRT), 134, 159

Cardiac syndrome X, 78

Cardio-oncology, 117

Cardiorespiratory fitness, 174

Cardiotoxicity, 121

Cardiovascular disease (CVD)
 after preeclampsia, 14–16
 breast cancer
 baseline risk factors, 120
 BRCA mutation carriers, 120
 death, 118
 multiple-hit hypothesis, 118
 optimal cardiac surveillance and treatment, 122–124
 patient surveillance, 119
 with anti-angiogenic and endocrine therapy, 122

clinical manifestations, 1–2

critical illness
 gender differences outcomes, 236–239
 immune response, 240–241
 intensive care, 242
 patients with, 235

diabetes mellitus, 9–11

dyslipidemia and statin, 6–8

female-specific risk factors
 age at menarche, 11, 12
 GDM, 13
 hormonal and reproductive status, 11
 PCOS, 12–13
 premature ovarian insufficiency and menopause, 13–14
 vascular damage after hypertensive pregnancy disorders, 12

hypertension, 8–9

migraine, 17–18

physical and pharmacological differences, 236, 240

risk factors
 age and lifetime, 6
 gender-shift in, 5
 goals and target levels, 3
 lifestyle, 2–3
 non-traditional, 16–17
 for premature, 3–5

Carotid stenosis, 192

Cerebral venous thrombosis, 190–191

CHA₂DS₂-VASc risk score, 157–158

Chemotherapy, 121

Chest pain
 anxiety, 211–212
 mechanisms, 211–212
 panic attack, 210–211
 symptoms, 209–210

CMD. *See* Coronary microvascular dysfunction (CMD)

Cognitive disorder, definition and demographics, 185

Computed tomographic angiography (CTA), 43

Coronary angiography, 44

Coronary artery bypass grafting (CABG), 47–48

Coronary artery disease (CAD), 37

Coronary flow reserve (CFR), 45, 80

Coronary microvascular dysfunction (CMD), 17
 clinical and pathogenic classifications, 78
 diagnostic testing, 80–81
 risk factors, 79
 symptom evaluation, 78–79
 therapeutic options, 81–82

Coronary reactivity testing (CRT), 80

Coronary Vasomotion Disorders International Study Group (COVADIS), 45

CVD. *See* Cardiovascular disease (CVD)

CYP3A4 inhibitors, 222

D

DCM. *See* Dilated cardiomyopathy (DCM)

Dementia, 185

Depression, 187, 204

Diabetes mellitus, 9–11

Diastolic dysfunction, 109, 240

Diet, 176

Dilated cardiomyopathy (DCM)
 clinical problem and pathophysiology, 132–133
 diagnostic pathway, 133
 outcomes, 135
 treatment, 134–135

Diuretics, 129

Dobutamine, 240

Dyslipidemia, 6–8

Dyspnoea, 108

E

Echocardiography, 109, 129
 aortic stenosis, 142–143
 mitral regurgitation, 145

Ejection fraction (EF), 122

Electrocardiography (ECG)
 atrial fibrillation, 157–158
 characteristics, 154
 corrected QT, 154
 CRT therapy, 159
 heart rate, 154
 ICD, 159
 paroxysmal supraventricular tachycardias,
 155–157
 screening mammograms, 160
 sex-related differences, 153, 155
 ventricular arrhythmias, 158–159
 Endocrine therapy, 122
 Endometriosis, 90
 Endothelial dysfunction, 91, 108
 Estrogens, 11, 88, 208, 224, 240–241
 Ethnic minorities, 178
 Extracorporeal cardiac support, 240

F

Fibromuscular dysplasia (FMD), 63–65
 Fibrosis, 110
 Flow-mediated vasodilatation (FMD), 45
 Fractional flow reserve (FFR), 44

G

Gestational diabetes mellitus (GDM), 13
 Glomerular filtration rate (GFR), 223

H

HCM. *See* Hypertrophic cardiomyopathy (HCM)
 Heart failure (HF), 2
 lifetime risk, 107
 myocardial remodelling with ageing, 108
 Heart failure with preserved ejection fraction (HFpEF)
 developments, 111–113
 diagnosis, 109
 fibrosis, 110
 inflammation, 110
 management, 110–111
 pathophysiology, 109–110
 prognosis, 108
 symptoms, 108
 Heart failure with reduced ejection fraction (HFrEF), 108
 Heart rate variability (HRV), 211–212
 Heart transplantation, 134–135
 HFpEF. *See* Heart failure with preserved ejection fraction (HFpEF)
 Hormone replacement therapy (HRT), 189
 Hormone therapy (HT), 96–97

Hospital Anxiety and Depression Scale (HADS), 173
 HPD. *See* Hypertensive pregnancy disorders (HPD)
 Hypertension
 menopause transition, 91–92
 treatment, 8–9
 Hypertensive pregnancy disorders (HPD), 13, 14
 Hypertrophic cardiomyopathy (HCM), 135–136
 clinical problem, 136–137
 diagnostic pathway, 137
 treatment, 137
 Hysterectomy, 90

I

Idiopathic dilated cardiomyopathy (IDC), 128
 IHD. *See* Ischemic heart disease (IHD)
 Immunomodulation, 241
 Implantable defibrillator devices (ICD), 159
 Inflammation, 110, 208, 241
 Intravascular ultrasound (IVUS), 78
 Ischemic heart disease (IHD), 2
 anxiety, 204
 CAD, 205
 chest pain
 anxiety, 211–212
 mechanisms, 211–212
 panic attack, 210–211
 symptoms, 209–210
 CMD, 206
 coronary angiography, 44, 77–78
 depression, 204
 development, 36
 diagnosis, 36–41
 elective percutaneous coronary intervention, 44
 fractional flow reserve, 44
 gender differences, 33–35
 guidance, 43
 invasive testing, 45–46
 NOCAD, 35–36
 non-invasive testing, 41–44
 psychological complaints, 203–204
 psychological distress, 210
 psychosocial risk factors, 205, 207–208
 sex differences, 33–35, 206–207
 socioeconomic status, 204
 spectrum of factors, 36
 stable angina pectoris, 47
 surgical treatment, 47–48
 treatment, 212–213
 Ischemic stroke, 184

L

- Labetalol, 190
- LCZ696, 113
- Left ventricular end-diastolic pressure (LVEDD), 109–110
- Loneliness, 204
- Long QT-syndrome (LQTS), 159
- LV adaptation, 143
- LV-assisted device (LVAD), 130

M

- Medical therapy, 134
- Medication adherence, 226–227
- Menopause, 87–88, 189
 - abnormal uterine bleeding, 95
 - in BRCA1/2 mutation carriers, 90
 - cardiovascular disease risk, 89
 - elevated blood pressure, 93–95
 - endometriosis, 90
 - endothelial dysfunction, 91
 - hormone therapy, 96–97
 - hypertension, 91–92
 - hysterectomy, 90
 - premature, 89–90
 - vasomotor symptoms, 89
 - VTE, 95
- Menstrual cycle, 154
- Microvascular angina, 78
- Migraine
 - CVD, 17–18
 - stroke, 188
- Mitral regurgitation (MR)
 - cause, 145
 - diagnosis, 145–146
 - in Europe, 144
 - treatment, 146–147
- Myocardial infarction with no obstructive coronary arteries' (MINOCA), 57
- Myocardial stiffness, 109–110

N

- Non-obstructive coronary artery disease (NOCAD), 35–36, 77, 78
- Novel oral anticoagulants (NOACs), 158, 188

O

- Obesity, 175–176
- Oral contraceptives, 60
 - menopause, 95
 - pharmacokinetics, 224
 - stroke, 189

P

- Panic attack, 210–211
- Paroxysmal supraventricular tachycardias (PSVT), 155–157
- PCOS. *See* Polycystic ovary syndrome (PCOS)
- Peripartum cardiomyopathy (PPCM)
 - clinical problem, 128
 - diagnostic pathway, 129
 - epidemiological study, 128
 - predisposing factors, 127–128
 - pregnancy neo-angiogenesis, 128
 - treatment, 129–131
- Pharmacodynamics, 222–223
- Pharmacokinetics, 236
 - ADR, 225–226
 - clinical cases, 228–230
 - gender difference
 - in adherence, 226–227
 - drug-drug interaction, 227–228
 - medical treatment advice, 230
 - during pregnancy
 - drug treatment, 227
 - oral contraceptives, 224
 - randomized controlled trials, 225
 - properties, 221–222
 - sex-differences, 222–223
- Pharmacotherapy, 221
- Phosphodiesterase-5 inhibitors (PDE-5), 112
- Polycystic ovary syndrome (PCOS), 12–13
- Post-traumatic stress disorder (PTSD), 242
- PPCM. *See* Peripartum cardiomyopathy (PPCM)
- Preeclampsia, 190
- Premature cardiovascular diseases (CVD), 3–5
- Premature ovarian failure (POF), 89–90
- Primary ovarian insufficiency (POI), 89–90
- Prolactin, 128
- Psychosocial stress, 176–177, 187

R

- Radiation therapy, 121

S

- SCAD. *See* Spontaneous coronary artery dissection (SCAD)
- Sepsis, 240
- Sex-hormones, 92, 224–225, 240
- Soluble guanylate cyclase (sGC-) stimulators, 112
- Spiroinolacton, 111–112

- Spontaneous coronary artery dissection (SCAD)
 coronary artery in, 62
 fibromuscular dysplasia, 63–65
 prevalence, 61
- Statins, 6–8
- Stress, 207
- Stroke
 atrial fibrillation, 187–188
 cerebral venous thrombosis, 190–191
 clinical practice, 191
 definition and demographics, 183–184
 diagnostic pathway, 191–192
 female-specific risk factors
 hormonal therapy, 189
 oral contraceptives, 189
 pregnancy, 189–190
 migraine, 188
 risk factors, 185–187
 treatment
 acute treatment, 194
 primary prevention, 193–194
 secondary prevention, 195
- Subarachnoidal hemorrhage (SAH), 184
- Supraventricular tachycardia (SVT), 156
- Surgical aortic valve replacement (SAVR), 144
- Systolic heart failure, 129
- T**
- Takotsubo cardiomyopathy (TTC), 65–67
- Tele-health, 178
- Thrombectomy, 191
- Thrombolysis, 190
- Torsade de pointes (TdP), 154, 225, 240
- Transcatheter aortic valve replacement (TAVR), 144
- Transesophageal (TEE) echocardiography, 145
- Transient ischemic attack (TIA), 2
- Transitory ischemic attack (TIA), 184
- Transthoracic Doppler echocardiography (TTDE), 80–81
- Transthoracic echocardiography (TTE), 145
- Transvalvular flow, 143
- Trastuzumab, 121–122
- Trauma, 240
- TTC. *See* Takotsubo cardiomyopathy (TTC)
- Type D personality, 204
- Type II ACS, 56, 57
- Type II diabetes (T2DM), 9–10
- V**
- Valvular heart disease
 aortic stenosis
 diagnosis, 142–144
 epidemiology, 142
 treatment, 144
 mitral regurgitation
 cause, 145
 diagnosis, 145–146
 in Europe, 144
 treatment, 146–147
 technical development, 141
- Vasomotor symptoms (VMS), 89
- Vasospasm, 79
- Venous thrombo-embolism (VTE), 95
- Ventricular arrhythmias, 158–159
- Ventricular assist device (VAD), 134
- W**
- Weight loss, 175–176
- Women's Ischemia Syndrome Evaluation (WISE) study, 207